Mednax INC Com (MD) Share Value Declined While Ipg Investment Advisors LLC Has Decreased Holding

June 7, 2018 - By Clifton Ray


Ipg Investment Advisors Llc decreased its stake in Mednax Inc Com (MD) by 32.66% based on its latest 2018Q1 regulatory filing with the SEC. Ipg Investment Advisors Llc sold 117,310 shares as the company’s stock declined 15.90% with the market. The institutional investor held 241,890 shares of the health care company at the end of 2018Q1, valued at $13.46B, down from 359,200 at the end of the previous reported quarter. Ipg Investment Advisors Llc who had been investing in Mednax Inc Com for a number of months, seems to be less bullish one the $4.33 billion market cap company. The stock decreased 0.21% or $0.1 during the last trading session, reaching $46.3. About 46,376 shares traded. MEDNAX, Inc. (NYSE:MD) has declined 15.55% since June 7, 2017 and is downtrending. It has underperformed by 28.12% the S&P500.

Ipg Investment Advisors Llc, which manages about $978.63M and $306.84B US Long portfolio, upped its stake in Spdr Gold Tr Gold Shs (GLD) by 4,401 shares to 35,481 shares, valued at $4.46 billion in 2018Q1, according to the filing. It also increased its holding in Facebook Inc Cl A (NASDAQ:FB) by 4,263 shares in the quarter, for a total of 67,952 shares, and has risen its stake in Palo Alto Networks Inc Com (NYSE:PANW).

Analysts await MEDNAX, Inc. (NYSE:MD) to report earnings on July, 27. They expect $1.00 earnings per share, up 25.00 % or $0.20 from last year’s $0.8 per share. MD’s profit will be $93.46M for 11.58 P/E if the $1.00 EPS becomes a reality. After $0.81 actual earnings per share reported by MEDNAX, Inc. for the previous quarter, Wall Street now forecasts 23.46 % EPS growth.

More news for MEDNAX, Inc. (NYSE:MD) were recently published by:, which released: “MedData (MD) Names Emily Fisher as Acting President” on June 01, 2018.‘s article titled: “MEDNAX to Present at the Jefferies 2018 Global Healthcare Conference” and published on June 01, 2018 is yet another important article.

MEDNAX, Inc. (NYSE:MD) Ratings Coverage

Among 10 analysts covering Mednax (NYSE:MD), 3 have Buy rating, 0 Sell and 7 Hold. Therefore 30% are positive. Mednax had 13 analyst reports since December 13, 2017 according to SRatingsIntel. The stock of MEDNAX, Inc. (NYSE:MD) earned “Neutral” rating by Citigroup on Friday, May 4. The firm earned “Market Perform” rating on Monday, February 12 by BMO Capital Markets. The company was maintained on Thursday, February 8 by Robert W. Baird. The company was maintained on Thursday, February 8 by Piper Jaffray. The company was maintained on Wednesday, January 24 by Mizuho. JP Morgan maintained it with “Neutral” rating and $55 target in Monday, February 12 report. The rating was maintained by Credit Suisse with “Neutral” on Monday, May 7. SunTrust maintained MEDNAX, Inc. (NYSE:MD) rating on Wednesday, December 20. SunTrust has “Hold” rating and $55.0 target. Mizuho maintained the shares of MD in report on Friday, February 9 with “Hold” rating. As per Thursday, February 8, the company rating was maintained by Stephens.

MEDNAX, Inc. (NYSE:MD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.